Advertisement

Clinical Pharmacokinetics

, Volume 58, Issue 4, pp 525–533 | Cite as

Pharmacokinetics of Hydroxychloroquine in Pregnancies with Rheumatic Diseases

  • Stephen J. BalevicEmail author
  • Thomas P. Green
  • Megan E. B. Clowse
  • Amanda M. Eudy
  • Laura E. Schanberg
  • Michael Cohen-Wolkowiez
Original Research Article
  • 126 Downloads

Abstract

Background

Hydroxychloroquine is an oral drug prescribed to pregnant women with rheumatic disease to reduce disease activity and prevent flares. Physiologic changes during pregnancy may substantially alter drug pharmacokinetics. However, the effect of pregnancy on hydroxychloroquine disposition and the potential need for dose adjustment remains virtually unknown.

Methods

We performed a population-pharmacokinetic analysis using samples from the Duke Autoimmunity in Pregnancy Registry from 2013 to 2016. We measured hydroxychloroquine concentration using high-performance liquid chromatography/tandem mass spectrometry and analyzed data using non-linear mixed-effect modeling. We calculated differences between pregnancy and postpartum empirical Bayesian estimates using paired t tests. We computed steady-state concentration profiles for hydroxychloroquine during pregnancy and postpartum using individual clinical data and empirical Bayesian estimates developed from the final pharmacokinetic model.

Results

We obtained 145 serum samples from 50 patients, 25 of whom had paired pregnancy and postpartum specimens. Five subjects had average concentrations (pregnancy and postpartum) < 100 ng/mL, consistent with medication non-adherence, and were excluded. The population estimated apparent volume of distribution was 1850 L/70 kg and estimated apparent clearance was 51 L/h. Compared with postpartum, median apparent volume of distribution increased significantly during pregnancy (p < 0.001), whereas apparent clearance and 24-h area under the curve did not change.

Conclusions

We developed a one-compartment population-pharmacokinetic model for hydroxychloroquine in pregnant women with rheumatic disease. Estimates for serum CL were within the expected range for plasma in non-pregnant adults. Because CL and 24-h area under the curve did not change during pregnancy compared with postpartum, our modeling in this small cohort does not support adjusting hydroxychloroquine dose during pregnancy.

Notes

Compliance with Ethical Standards

Funding

Salary and/or research support for this project was provided by the Rheumatology Research Foundation’s Scientist Development Award, the Thrasher Research Fund, the Derfner Foundation, NIGMS/NICHD (2T32GM086330-06), NICHD (5R01-HD076676-04, HHSN275201000003I), and a Duke Health/Private Diagnostic Clinic ENABLE grant. The National Institutes of Health Sponsored open access.

Conflict of interest

Stephen J. Balevic receives salary and research support from the National Institute of General Medical Sciences and the National Institute of Child Health and Human Development (2T32GM086330-06, 5R01-HD076676-04, HHSN275201000003I), the Rheumatology Research Foundation, and the Thrasher Research Fund. Michael Cohen-Wolkowiez receives support for research from the National Institutes of Health (5R01-HD076676, HHSN275201000003I), National Institute of Allergy and Infectious Diseases/National Institutes of Health (HHSN272201500006I), US Food and Drug Administration (1U18-FD006298), Biomedical Advanced Research and Development Authority (HHSO1201300009C), and from the industry for the drug development in adults and children (http://www.dcri.duke.edu/research/coi.jsp). Amanda M. Eudy is a consultant for GlaxoSmithKline and was previously a graduate research assistant for GlaxoSmithKline. Megan E. B. Clowse and Amanda M. Eudy have received independent medical education Grants from GlaxoSmithKline. Thomas P. Green has no conflicts of interest directly relevant to the contents of this article. Laura E. Schanberg receives research support from the National Institutes of Health (5R01-AR063890-02, 1U19AR069522-01, 1U34AR066294), Patient-Centered Outcomes Research Institute (CER-1408-20534, PPRN-1306-04601), Childhood Arthritis and Rheumatology Research Alliance, and Swedish Orphan Biovitrum AB. She participates in the Data Safety and Monitoring Board for UCB and Sanofi. Megan E. B. Clowse serves as a consultant for UCB and AstraZeneca.

Ethics approval

We conducted the study in compliance with the Declaration of Helsinki and the Duke Institutional Review Board approved the protocol.

Informed consent

All subjects included in the study provided informed consent.

Supplementary material

40262_2018_712_MOESM1_ESM.pdf (230 kb)
Supplementary material 1 (PDF 230 kb)
40262_2018_712_MOESM2_ESM.doc (26 kb)
Supplementary material 2 (DOC 26 kb)

References

  1. 1.
    Clowse ME. Lupus activity in pregnancy. Rheum Dis Clin N Am. 2007;33:237–52.CrossRefGoogle Scholar
  2. 2.
    Gotestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75:795–810.CrossRefPubMedGoogle Scholar
  3. 3.
    Clowse ME, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 2006;54:3640–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Eudy AM, Siega-Riz AM, Engel SM, Franceschini N, Howard AG, Clowse MEB, et al. Effect of pregnancy on disease flares in patients with systemic lupus erythematosus. Ann Rheum Dis. 2018;77:855–60.PubMedGoogle Scholar
  5. 5.
    Fischer-Betz R, Specker C, Brinks R, Aringer M, Schneider M. Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine. Rheumatology (Oxford). 2013;52:1070–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Ke AB, Rostami-Hodjegan A, Zhao P, Unadkat JD. Pharmacometrics in pregnancy: an unmet need. Annu Rev Pharmacol Toxicol. 2014;54:53–69.CrossRefPubMedGoogle Scholar
  7. 7.
    Abduljalil K, Furness P, Johnson TN, Rostami-Hodjegan A, Soltani H. Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling. Clin Pharmacokinet. 2012;51:365–96.CrossRefPubMedGoogle Scholar
  8. 8.
    Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology. 2015;23:231–69.CrossRefPubMedGoogle Scholar
  9. 9.
    Browning DJ. Pharmacology of chloroquine and hydroxychloroquine. In: Hydroxychloroquine and chloroquine retinopathy. New York: Springer New York; 2014. pp. 35–63.Google Scholar
  10. 10.
    NMS Labs. Hydroxychloroquine test summary sheet. http://www.nmslabs.com/tests/Hydroxychloroquine–Serum-Plasma/2362SP. Accessed 6 Feb 2018.
  11. 11.
    Lim HS, Im JS, Cho JY, Bae KS, Klein TA, Yeom JS, et al. Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. Antimicrob Agents Chemother. 2009;53:1468–75.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Morita S, Takahashi T, Yoshida Y, Yokota N. Population pharmacokinetics of hydroxychloroquine in Japanese patients with cutaneous or systemic lupus erythematosus. Ther Drug Monit. 2016;38:259–67.CrossRefPubMedGoogle Scholar
  13. 13.
    Costedoat-Chalumeau N, Amoura Z, Hulot JS, Aymard G, Leroux G, Marra D, et al. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann Rheum Dis. 2007;66:821–4.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Costedoat-Chalumeau N, Le Guern V, Piette JC. Routine hydroxychloroquine blood concentration measurement in systemic lupus erythematosus reaches adulthood. J Rheumatol. 2015;42:1997–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Iudici M, Pantano I, Fasano S, Pierro L, Charlier B, Pingeon M, et al. Health status and concomitant prescription of immunosuppressants are risk factors for hydroxychloroquine non-adherence in systemic lupus patients with prolonged inactive disease. Lupus. 2018;27:265–72.CrossRefPubMedGoogle Scholar
  16. 16.
    Carmichael SJ, Charles B, Tett SE. Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. Ther Drug Monit. 2003;25:671–81.CrossRefPubMedGoogle Scholar
  17. 17.
    Tett SE, Cutler DJ, Day RO, Brown KF. A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers. Br J Clin Pharmacol. 1988;26:303–13.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Jallouli M, Galicier L, Zahr N, Aumaitre O, Frances C, Le Guern V, et al. Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. Arthritis Rheumatol. 2015;67:2176–84.CrossRefPubMedGoogle Scholar
  19. 19.
    Yeon Lee J, Lee J, Ki Kwok S, Hyeon JuJ, Su Park K, Park SH. Factors related to blood hydroxychloroquine concentration in patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2017;69:536–42.CrossRefPubMedGoogle Scholar
  20. 20.
    Hebert MF, Zheng S, Hays K, Shen DD, Davis CL, Umans JG, et al. Interpreting tacrolimus concentrations during pregnancy and postpartum. Transplantation. 2013;95:908–15.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Costedoat-Chalumeau N, Houssiau F, Izmirly P, Le Guern V, Navarra S, Jolly M, et al. A prospective international study on adherence to treatment in 305 patients with flaring SLE: assessment by drug levels and self-administered questionnaires. Clin Pharmacol Ther. 2018;103(6):1074–82.CrossRefPubMedGoogle Scholar
  22. 22.
    Durcan L, Clarke WA, Magder LS, Petri M. Hydroxychloroquine blood levels in systemic lupus erythematosus: clarifying dosing controversies and improving adherence. J Rheumatol. 2015;42:2092–7.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Costedoat-Chalumeau N, Amoura Z, Hulot JS, Hammoud HA, Aymard G, Cacoub P, et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54:3284–90.CrossRefPubMedGoogle Scholar
  24. 24.
    Tett SE, Cutler DJ, Beck C, Day RO. Concentration-effect relationship of hydroxychloroquine in patients with rheumatoid arthritis: a prospective, dose ranging study. J Rheumatol. 2000;27:1656–60.PubMedGoogle Scholar
  25. 25.
    Munster T, Gibbs JP, Shen D, Baethge BA, Botstein GR, Caldwell J, et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum. 2002;46:1460–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Lee JY, Vinayagamoorthy N, Han K, Kwok SK, Ju JH, Park KS, et al. Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2016;68:184–90.CrossRefPubMedGoogle Scholar
  27. 27.
    Shaw E, Kaczorowski J. Postpartum care: what’s new? Curr Opin Obstet Gynecol. 2007;19:561–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Duke Clinical Research InstituteDuke University School of MedicineDurhamUSA
  2. 2.Department of PediatricsDuke University School of MedicineDurhamUSA
  3. 3.Department of MedicineDuke University School of MedicineDurhamUSA
  4. 4.Department of PediatricsNorthwestern University/Ann and Robert H. Lurie Children’s HospitalChicagoUSA
  5. 5.Divisions of Adult and Pediatric RheumatologyDuke University Medical CenterDurhamUSA

Personalised recommendations